53

Auro Laboratories LtdBOM 530233 Stock Report

Last reporting period 31 Mar, 2024

Updated 28 Oct, 2024

Last price

Market cap $B

0.006

Micro

Exchange

XBOM - Bombay Stock Exchange

530233.BO Stock Analysis

53

Neutral

Based on Eyestock quantitative analysis, 530233.BO`s fundamental data and valuation indicate an investment grade of Neutral at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

85/100

Moderate score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

-26.1 %

Overvalued

Market cap $B

0.006

Dividend yield

Shares outstanding

6.23 B

Auro Laboratories Ltd. engages in the manufacture of active pharmaceutical ingredients, intermediates and generic formulations. The company is headquartered in Mumbai, Maharashtra. The firm operates through the Pharmaceuticals segment. The company offers APIs under categories, such as antihistamine, muscle relaxant, diuretic, iron deficiency, anti-diabetic, anti-fungal, anti-ulcer, iodine supplement, anti-malaria, analgesics, antacids anti-inflammatory and others. Its products under intermediates include Glibenclamde Sulphonamide, Cis-bramo benzoate, Cls-Tosylate, 2-Ethoxy Benzoic Acid, 3,4,5, Trimethoxy Benzoic Acid and 5-Bromo Phthalide. The company also undertakes toll/custom manufacturing for APIs and Intermediates on contract basis. The firm has a presence in international markets with bulk of its production being exported to Southeast Asia, Middle East and several European Countries. Some of the countries it exports to are Egypt, Germany, Malaysia, Singapore, South Africa, Brazil, Spain and United Kingdom.

View Section: Eyestock Rating